Loading...
NPI 1316378789 · Mentor, OH · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Center For Molecular Cancer Diagnostics, Inc is a clinical medical laboratory provider located in Mentor, Ohio. This profile covers 99 Medicare and 64 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Center For Molecular Cancer Diagnostics, Inc |
| Address | 7956 Tyler Blvd |
| City | Mentor |
| State | OH |
| ZIP | 44060 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 10, 2013 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $4.6M |
| Medicare | $2.8M |
CENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC’s code mix is concentrated in amplified nucleic acid probe and multiplex molecular assays, indicating it operates as a specialty clinical molecular laboratory focused on infectious disease diagnostics. Its top Medicare codes (87798, 87481, 87507) and top Medicaid codes (87798, U0004, 87633) are all molecular or high-throughput pathogen tests, which signals a lab workflow built around nucleic-acid amplification and multiplex panels rather than routine chemistry or anatomic pathology services.
Revenue concentration on Medicare is high: the precomputed top 3 Medicare codes by revenue account for 68.3% of this provider's total Medicare revenue, with 87798 alone contributing $1.1M (42.5% of Medicare revenue). This concentration implies that a relatively small number of molecular assays drive most Medicare receipts for this provider, making overall Medicare revenue sensitive to utilization or reimbursement changes for those specific codes.
Medicaid revenue is similarly concentrated: the precomputed top 3 Medicaid codes by revenue account for 69.7% of the provider's total Medicaid revenue, with 87798 at $1.4M (30.5%), U0004 at $1.2M (25.9%), and 87633 at $611.1K (13.3%). The Medicaid mix shows a major reliance on both generic amplified-probe testing and COVID high-throughput testing, indicating payer-specific demand for pandemic-related and multiplex respiratory/GI panels.
This provider’s payer mix is Medicaid-dominant in scale: lifetime Medicaid revenue is $4.6M versus Medicare revenue of $2.8M, so Medicaid represents the larger share of billed public-payer volumes and revenue. That asymmetry suggests contracts, client relationships, or testing volumes are weighted toward Medicaid-covered populations or state public health testing channels.
National competitive standing on Medicare is mixed by code: the provider ranks notably above typical national volume for specialized panels such as 87507 (ranks #3 of 60 nationally, 97th percentile) and 87651 (ranks #32 of 3530 nationally, 99th percentile), while its largest Medicare code 87798 ranks #60 of 1319 providers nationally (96th percentile) and is described as typical, unremarkable volume. In practice this means the lab is a national high-volume performer for select multiplex assays but a more typical participant on broader generic probe testing.
State-level standing on Medicaid shows clear dominance for specific assays: the provider is an extreme outlier or top-ranked in-state for multiple codes (for example, 87641 MRSA ranks #1 of 50 in-state, 100th percentile; 87486 ranks #1 of 47, 100th percentile; several other codes rank #1 in-state or in the top few), and U0004 COVID testing ranks #3 of 43 in-state (95th percentile, notably above typical). These rankings indicate the lab is a major in-state provider for molecular infectious-disease testing and high-throughput COVID services.
Operationally, Medicaid claim volumes reflect very large test throughput for public-payer COVID and screening panels: U0004 shows 18.9K claims and 87798 shows 10.2K claims in Medicaid data, and other screening codes (87653 9.9K claims, 87641 8.4K claims) also have multi-thousand claim counts. Those high claim volumes coupled with the Medicaid revenue scale imply established specimen logistics and high-throughput processing capacity oriented to population-level screening and outbreak response.
The provider’s NPI tenure (NPI enumerated 2013-12-10 (~13 years ago)) combined with lifetime public-payer revenue of $2.8M (Medicare) and $4.6M (Medicaid) suggests an established, mid-sized specialty molecular lab rather than a new entrant. The sustained revenue and concentrated code mix point to a mature operation with defined niches in multiplex pathogen panels and state-level COVID and screening services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
99 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 32,740 | $30 | $1.1M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 11,460 | $30 | $389.6K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 700 | $410 | $284K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 4,640 | $30 | $157.8K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 2,560 | $30 | $87.1K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 2,480 | $30 | $84.2K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 2,460 | $30 | $83.7K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 2,190 | $30 | $74.5K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 390 | $140 | $54.6K |
| 87556 | The lab analyst performs a test for Mycobacterium tuberculosis using amplified nucleic acid probe technique. Mycobacteria tuberculosis are sometimes called acid fast bacteria because of the special… | 980 | $40 | $40.2K |
Showing 1–10 of 99
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 99 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
64 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 10,240 | $140 | $1.4M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 18,890 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 2,630 | $230 | $611.1K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 3,140 | $60 | $175.8K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,780 | $40 | $172K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 11,330 | $10 | $147.3K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 8,400 | $10 | $109.2K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 9,860 | $10 | $108.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 7,950 | $10 | $87.4K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 5,350 | $10 | $64.2K |
Showing 1–10 of 64
How this provider's Medicaid billing volume and revenue compare to other Ohio providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Ohio median
64 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 3 | 40 | 230 | $130 | $455.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 300 | 340 | 2,260 | $30 | $398.2K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 230 | 270 | 8,700 | $10 | $353.7K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 219 | 240 | 2,610 | $10 | $239.7K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 10 | 60 | 240 | $160 | $215.8K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 77 | 220 | 1,080 | $20 | $214.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 76 | 220 | 1,050 | $20 | $202.4K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 263 | 280 | 1,450 | $10 | $178.3K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 4 | 60 | 310 | $130 | $152.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 40 | 140 | 960 | $20 | $146.1K |
Showing 1–10 of 64
Other providers in the same ZIP code as Center For Molecular Cancer Diagnostics, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Maxim Healthcare Services, Inc. | OH | Home Health Agency | $0 | $21.4M |
| Crossroads Health | OH | Community/Behavioral Health Agency | $0 | $14.8M |
| Lake-geauga Recovery Centers, Inc. | OH | Substance Abuse Rehabilitation Facility | $0 | $12.6M |
| A Heavenly Helper, LLC | OH | Home Health Agency | $0 | $7.9M |
| Tri-county Ambulance Service, Inc. | OH | Land Ambulance | $742.3K | $3.3M |
| City Of Mentor Lake County | OH | Ambulance | $678.1K | $830.2K |
| Endoscopy Center Of Lake County, LLC | OH | Ambulatory Surgical Clinic/Center | $407.7K | $916.3K |
| Mentor Surgery Center Ltd | OH | Ambulatory Surgical Clinic/Center | $692.7K | $33.4K |
| Shreeniwas Lele | OH | Internal Medicine Physician | $294.8K | $0 |
| Great Lakes Ambulatory Surgery Center | OH | Ambulatory Surgical Clinic/Center | $254.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.